University of Florida

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Florida sits in the top decile of US sponsors by registered trial count (#29 of 15,742 sponsors by registered trial count).

1,106 total trials 170 currently recruiting 754 completed early-phase tilt top decile by trial count

University of Florida: 1,106 sponsored US clinical trials, 170 recruiting.

University of Florida sponsors 1,106 registered US clinical trials on ClinicalTrials.gov, 170 of them currently recruiting, and 754 completed. 103 of these trials are in Phase 3-4 (later-stage) and 232 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Coronary Artery Disease, with 17 trials.

Top-decile sponsor footprint

University of Florida ranks in the top decile of sponsors by registered trial count (#29 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 60/100

754 of 855 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,106 total, page 18 of 23

COMPLETED

Study To Analyze Memory/Thinking Problems In Older Adults After Surgery

NCT01786577

COMPLETED Phase 2

Efficacy of Steroid Supplementation After TMJ Rinsing for Pain Management

NCT01770912

COMPLETED Phase 1

13C-Pyruvate Breath Test

NCT01807702

COMPLETED Early Phase 1

Assessment of Dystussia in Traumatic Brain Injury

NCT02240329

COMPLETED

Peroral Endoscopic Myotomy (POEM) for the Treatment of Achalasia

NCT01832779

COMPLETED NA

Pocket Echocardiography System (PES) for Detection of PDA in Neonates

NCT01790750

COMPLETED NA

Dalfampridine and Gait in Spinocerebellar Ataxias

NCT01811706

COMPLETED NA

Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes

NCT01852214

COMPLETED NA

Alveolar Microperforation for Inflammation-Enhanced Tooth Movement During Orthodontic Treatment

NCT01720797

COMPLETED NA

Occupational Therapy Driving Intervention for Returning Combat Veterans.

NCT02764983

COMPLETED NA

Impact of Ticagrelor Re-load on Pharmacodynamic Profiles

NCT01731041

COMPLETED

Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock

NCT02163473

TERMINATED

The Role of Non-Alcoholic Fatty Liver Disease in Gestational Diabetes

NCT01855386

COMPLETED Phase 3

Clinical Trial to Reduce Drinking in Women With HIV

NCT01625091

COMPLETED

Identify Clinical Conditions That Increase Circulating DNA Levels

NCT01815996

COMPLETED NA

Study of a Multimodality Pain Management Protocol on Postoperative Neurosurgical Pain

NCT01693588

COMPLETED NA

My Lifestyle Intervention of Food and Exercise

NCT01630499

COMPLETED NA

Cranberry Consumption Improves γδ T Cell Function

NCT01713829

COMPLETED

Oral Alkali Production and Caries Prevention in Children (Longitudinal)

NCT02398695

COMPLETED NA

The Effect of Probiotics (L. Helveticus, B. Longum, and B. Bifidum) on Immune Function and Digestive Health

NCT01709825

COMPLETED

Insights Into Deep Brain Stimulation (DBS) for Cervical Dystonia

NCT01671527

COMPLETED NA

Central Mechanisms of Intervention for Low Back Pain

NCT01406847

COMPLETED Phase 2

Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma

NCT01652976

COMPLETED NA

Evaluation of Bacillus Subtilis R0179 in Healthy Young Adults

NCT01802151

COMPLETED NA

Probiotics (L. Gasseri, B. Bifidum, B. Longum) on Immune and Intestinal Health in Healthy Older Adults

NCT01662206

TERMINATED

Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiotherapy

NCT01671163

TERMINATED

Feasibility Study of Tumor Blood Flow Measurement by Detection of Positron Activation Post Proton Therapy (DS01)

NCT01987193

COMPLETED NA

Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project

NCT02440906

COMPLETED

Periodontal Treatment Response in Type II Diabetic Patients

NCT01881074

COMPLETED

Can Short Latency Afferent Inhibition Give us Clues to Better DYT 1 Dystonia Treatments?

NCT01435681

COMPLETED Early Phase 1

Clinical Study to Evaluate the Role of Microdialysis for the Comparison of Topical Products

NCT01592019

COMPLETED NA

Proton Therapy for Lymph Nodes in Breast Cancer

NCT01365845

COMPLETED Phase 4

Tolvaptan for Ascites in Cirrhotic Patients

NCT01292304

COMPLETED NA

Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy

NCT01852162

COMPLETED NA

Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease

NCT01852175

COMPLETED

Laparoscopy-assisted ERCP in Patients With Altered Gastric Anatome

NCT01620632

TERMINATED Phase 3

Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)

NCT01487499

COMPLETED Phase 2

Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer

NCT01471353

TERMINATED

Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

NCT01494896

COMPLETED Phase 2

Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer

NCT01553019

COMPLETED NA

Immune Benefits From Mushroom Consumption

NCT01398176

COMPLETED Phase 2

Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma

NCT01470417

COMPLETED Phase 1

Ampicillin for DYT-1 Dystonia Motor Symptoms

NCT01433757

COMPLETED

Peak Impact Forces and Metabolic Cost During Mid-Forefoot Striking in Shod Versus Barefoot Runners

NCT01536171

COMPLETED NA

Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer

NCT01368055

COMPLETED NA

The Effect of Fiber Snack Foods on Dietary Intake in Healthy Adults

NCT01478659

TERMINATED NA

Pharmacotoxicology of Trichloroethylene Metabolites

NCT00865514

TERMINATED Phase 1

Investigations of Botanicals on Food Intake, Satiety, Weight Loss, and Oxidative Stress

NCT01238887

COMPLETED NA

Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia

NCT01621776

COMPLETED

Genetic Contribution of Pain and Inflammation in IBS

NCT01436760

← Previous Page 18 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 123
Phase 2 109
Phase 3 13
Phase 4 90

What is open in the University of Florida pipeline

170 recruiting of 1,106 indexed (15% open); 754 completed (68%).

Phase mix: 103 late (III/IV) vs 232 early (I/II) (early-phase heavy).

Top condition: Coronary Artery Disease (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Florida: open-pipeline peers nationwide

Peers matched on 1,106 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

University of Florida sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share University of FloridaUniversity of North Carolina, Chapel HillWake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthArrowhead Regional Medical CenterAurinia PharmaceuticalsBronx VA Medical CenterCandel Therapeutics
University of Florida sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Florida sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,106 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this University of Florida page

1,106 registered trials is a research-attention snapshot, not an endorsement of University of Florida or any single study.

  • 170 of University of Florida's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Coronary Artery Disease is the condition University of Florida studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronary Artery Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Florida pipeline card: 1,106 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.